Evaluation of Antibody Persistence Following a Primary Series at 2, 4, and 6 Months on Trial A3L24 and Booster Effect of the DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa Concomitantly Administered With Prevenar at 12 to 24 Months of Age in Healthy Latin American Infants

Trial Profile

Evaluation of Antibody Persistence Following a Primary Series at 2, 4, and 6 Months on Trial A3L24 and Booster Effect of the DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa Concomitantly Administered With Prevenar at 12 to 24 Months of Age in Healthy Latin American Infants

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Hib-DTaP-hepatitis B-poliovirus vaccine (Primary) ; Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa); Pneumococcal 7-valent CRM197 vaccine conjugate
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Pneumococcal infections; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Sponsors Sanofi; sanofi pasteur
  • Most Recent Events

    • 14 Jul 2017 Results evaluating primary (NCT01177722) and booster (NCT01444781) vacinations of healthy infants and toddlers in Latin America published in the Pediatric Infectious Disease Journal
    • 21 Jan 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
    • 20 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top